A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes

Author(s):  
Yuting Wang ◽  
Tahira Devji ◽  
Anila Qasim ◽  
Qiukui Hao ◽  
Vanessa Wong ◽  
...  
2011 ◽  
Vol 38 (8) ◽  
pp. 1699-1701 ◽  
Author(s):  
JOHN R. KIRWAN ◽  
PETER S. TUGWELL

This overview draws out the main conclusions from the 4 workshops focused on incorporating the patient perspective into outcome assessment at the 10th Outcome Measures in Rheumatology (OMERACT 10) conference. They raised methodological issues about the choice of outcome domains to include in clinical trials, the development or choice of instruments to measure these domains, and the way these instruments might capture the impact of a disease and its treatment. The need to develop a more rigorous conceptual model of quantifying the way conditions affect health, and the need to ensure patients are directly involved in the decisions about domains and instruments, emerged clearly. The OMERACT participants voted to develop guidelines for domain and instrument selection, and conceptual and experimental work will be brought forward to revise and upgrade the OMERACT Filter.


Author(s):  
Alonso Carrasco-Labra ◽  
Tahira Devji ◽  
Anila Qasim ◽  
Mark R. Phillips ◽  
Yuting Wang ◽  
...  

Medical Care ◽  
1994 ◽  
Vol 32 (Supplement) ◽  
pp. JS77 ◽  
Author(s):  
FLOYD J. FOWLER ◽  
PAUL D. CLEARY ◽  
JAY MAGAZINER ◽  
DONALD L PATRICK ◽  
KATY L. BENJAMIN

Author(s):  
Dennis A Revicki ◽  
David Cella ◽  
Ron D Hays ◽  
Jeff A Sloan ◽  
William R Lenderking ◽  
...  

2010 ◽  
Vol 37 (4) ◽  
pp. 816-822 ◽  
Author(s):  
LAURA WHEATON ◽  
JANET POPE

Objective.To study minimal important differences (MID) in spondyloarthropathies (SpA). MID are important in determining clinically relevant changes and for interpretation of trials and treating patients. MID have been widely studied in rheumatoid arthritis, but less so in SpA.Methods.Patients with SpA had to be seen for 2 consecutive visits and have completed the Health Assessment Questionnaire (HAQ) and 100 mm visual analog scale on both visits for fatigue, pain, sleep, and global assessment. At the second visit they had to answer a question regarding any change in their overall health (from last visit), responding with much better, better, same, worse, or much worse. The MID were the mean changes for those who were either better or worse.Results.Our study involved 140 eligible patients with a SpA: 69% were men, the mean age was 45 years, and the mean disease duration was 14.5 years. Almost half the patients rated themselves as unchanged from the previous visit but the remainder were either better or worse, with a minority rating themselves as much better or much worse. The MID for better and worse outcomes were HAQ (−0.136; 0.220), pain (−6.93; 18.97), fatigue (−1.43; 14.42), and sleep (−2.23; 10.76). No gender differences were observed.Conclusion.Our results demonstrate that the MID vary depending on better versus worse (bidirectionally different). MID may be smaller in clinical practice than what is observed in trials.


Sign in / Sign up

Export Citation Format

Share Document